Lenvatinib in Kombination mit Pembrolizumab (Nierenzellkarzinom)
- DOI
- 10.4126/frl01-006434944
- Published
- 2022
- Container
- Not recorded
- Publisher
- Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.4126/frl01-006434944,
title = {Lenvatinib in Kombination mit Pembrolizumab (Nierenzellkarzinom)},
author = {Grünwald, Viktor and Grimm, Marc-Oliver and Wörmann, Bernhard and Doehn, Christian and Krege, Susanne and Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie and Deutschland. Gemeinsamer Bundesausschuss and Bokemeyer, Carsten and Deutsche Gesellschaft Für Urologie and Bergmann, Lothar and Amsberg, Gunhild Von},
year = {2022},
doi = {10.4126/frl01-006434944},
url = {https://doi.org/10.4126/frl01-006434944}
}RIS
TY - JOUR TI - Lenvatinib in Kombination mit Pembrolizumab (Nierenzellkarzinom) AU - Grünwald, Viktor AU - Grimm, Marc-Oliver AU - Wörmann, Bernhard AU - Doehn, Christian AU - Krege, Susanne AU - Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie AU - Deutschland. Gemeinsamer Bundesausschuss AU - Bokemeyer, Carsten AU - Deutsche Gesellschaft Für Urologie AU - Bergmann, Lothar AU - Amsberg, Gunhild Von PY - 2022 DO - 10.4126/frl01-006434944 UR - https://doi.org/10.4126/frl01-006434944 ER -
APA
Viktor, G., Marc-Oliver, G., Bernhard, W., Christian, D., Susanne, K., Onkologie, D. G. F. H. U. M., Bundesausschuss, D. G., Carsten, B., Urologie, D. G. F., Lothar, B., & Von, A. G. (2022). Lenvatinib in Kombination mit Pembrolizumab (Nierenzellkarzinom). https://doi.org/10.4126/frl01-006434944
Source records
- datacite · retrieved 2026-09-27T06:58:36.606Z